Vertex Pharmaceuticals (VRTX)

Cost of Revenue

$1.76B

TTM · Period ending: · USD

VRTX logo

VRTX Cost of Revenue

Latest reported$1.76B
VRTX TTM Cost of Revenue ($0.00 → $1.76B)
High-resolution chart · PNG

VRTX cost of revenue history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Vertex Pharmaceuticals Cost of Revenue — Trailing twelve months (TTM) (USD)
Period endingCost of Revenue (USD)
1,762,800,000
1,681,100,000
1,651,300,000
1,608,700,000
1,586,500,000
1,550,900,000
1,530,500,000
1,475,100,000
1,401,200,000
1,337,900,000
1,262,200,000
1,177,500,000
1,148,200,000
1,101,400,000
1,080,300,000
1,044,400,000
991,512,000
957,684,000
904,213,000
859,914,000
809,584,000
766,132,000
736,300,000
718,211,000
663,943,000
615,163,000
547,758,000
485,035,000
464,376,000
433,018,000
409,539,000
371,302,000
332,921,000
299,744,000
275,119,000
251,549,000
232,752,000
206,799,000
210,460,000
214,393,000
192,276,000
163,884,000
125,542,000
75,154,000
57,378,000
57,818,000
60,987,000
69,224,000
82,379,000
103,010,000
130,277,000
195,728,000
206,925,000
283,417,000
279,885,000
222,297,000
222,167,000
117,050,000
80,505,000
53,427,000
18,249,000
12,029,000
12,730,000
13,328,000
13,812,000
13,993,000
14,202,000
14,770,000
15,252,000
15,686,000
15,686,000
15,143,000
14,511,000
14,211,000
13,904,000
13,409,000
12,960,000
12,444,000
12,170,000
11,776,000
11,459,000
11,063,000
10,098,000
9,324,000
7,994,000
6,833,000
5,649,000
-590,000
-405,000
-195,000
2,474,000
13,305,000
18,231,000
23,155,000
28,281,000
31,350,000
35,436,000
29,895,000
22,091,000
19,783,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.